Amneal Pharmaceuticals, Inc. (AMRX)
USD 7.69
(-4.71%)
USD 7.69
(-4.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 345.57 Million | 65.1 Million | 241.82 Million | 379 Million | 1.7 Million | 250.23 Million |
| Net Income | -48.72 Million | -254.78 Million | 20.17 Million | 68.57 Million | -603.57 Million | -201.3 Million |
| Depreciation & Amortization | 229.4 Million | 240.17 Million | 233.4 Million | 235.38 Million | 207.23 Million | 137.4 Million |
| Deferred income taxes | 94.33 Million | - | 83.38 Million | 95.64 Million | 371.71 Million | -9.43 Million |
| Stock-based compensation | 26.82 Million | 31.84 Million | 28.41 Million | 20.75 Million | 21.67 Million | 167.59 Million |
| Change in working capital | -47.18 Million | -59.94 Million | -133.59 Million | -61.31 Million | -120.21 Million | 7.01 Million |
| Other non-cash items | 90.92 Million | 107.81 Million | 10.03 Million | 19.96 Million | 124.86 Million | 148.96 Million |
| Investing Cash Flow | -69.18 Million | -174.3 Million | -194.18 Million | -317.54 Million | -19.58 Million | -396.37 Million |
| Investments in PPE | -69.18 Million | -90.59 Million | -52.63 Million | -66.18 Million | -97.43 Million | -97.08 Million |
| Acquisitions | - | -84.71 Million | -146.54 Million | -251.36 Million | 34.83 Million | -324.63 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -25.97 Million | 1 Million | 5 Million | -255.71 Million | 43.01 Million | 25.34 Million |
| Financing Cash Flow | -212.57 Million | -106.62 Million | -138.12 Million | 131.8 Million | -45.83 Million | 287.67 Million |
| Debt repayment | -414.08 Million | -123.27 Million | -79.17 Million | -37.01 Million | -29.27 Million | -784.33 Million |
| Dividends payments | - | - | - | - | - | -182.99 Million |
| Common Stock Repurchased | -2.37 Million | -3.57 Million | -2.66 Million | -863 Thousand | -926 Thousand | - |
| Common Stock Issuance | - | 662 Thousand | - | - | - | - |
| Other Financing Activities | 201.5 Million | 23.13 Million | -56.27 Million | 169.68 Million | -15.63 Million | 1.25 Billion |
| Accounts receivables | 126.28 Million | -79.71 Million | -23.62 Million | 16.78 Million | -132.72 Million | 89.08 Million |
| Accounts payables | -94.44 Million | 109.56 Million | -43.93 Million | 307 Thousand | -10.25 Million | -55.21 Million |
| Inventory | -126.18 Million | -102.39 Million | -49.01 Million | -113.78 Million | -20.39 Million | -42.87 Million |
| Other working capital | 94.33 Million | 12.6 Million | -17.02 Million | 35.37 Million | 43.15 Million | 16.01 Million |
| Cash at beginning of period | 35.22 Million | 256.73 Million | 347.12 Million | 152.82 Million | 218.77 Million | 77.92 Million |
| Cash at end of period | 99.1 Million | 35.22 Million | 256.73 Million | 347.12 Million | 152.82 Million | 218.77 Million |
| Capital Expenditure | -69.18 Million | -90.59 Million | -52.63 Million | -66.18 Million | -97.43 Million | -97.08 Million |
| Effect of forex changes on cash | 65 Thousand | -5.68 Million | 102 Thousand | 1.03 Million | -2.24 Million | -670 Thousand |
| Net cash flow / Change in cash | 63.88 Million | -221.51 Million | -90.38 Million | 194.29 Million | -65.95 Million | 140.85 Million |
| Free Cash Flow | 276.38 Million | -25.49 Million | 189.18 Million | 312.81 Million | -95.72 Million | 153.14 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 16.78 Million | -81.67 Million | -48.72 Million | -93.34 Million | 25.03 Million | 29.68 Million |
| Depreciation & Amortization | 55.57 Million | 55.52 Million | 229.4 Million | 56.93 Million | 57.2 Million | 57.11 Million |
| Deferred income taxes | - | - | 94.33 Million | 9.88 Million | -2.07 Million | -23 Thousand |
| Stock-based compensation | 6.72 Million | 6.72 Million | 26.82 Million | 5.97 Million | 6.69 Million | 6.56 Million |
| Change in working capital | -56.71 Million | -11.97 Million | -47.18 Million | 53.7 Million | -34.73 Million | -120.42 Million |
| Other non-cash items | -1.84 Million | 26.99 Million | 90.92 Million | 102.67 Million | 29.27 Million | 15.75 Million |
| Investing Cash Flow | -6.46 Million | -19.76 Million | -69.18 Million | -31.69 Million | -13.47 Million | -12.28 Million |
| Investments in PPE | -11.45 Million | -19.76 Million | -69.18 Million | -31.69 Million | -13.47 Million | -12.28 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 4.23 Million | -9.7 Million | -25.97 Million | -25.97 Million | - | -1.15 Million |
| Financing Cash Flow | -35.08 Million | -23.15 Million | -212.57 Million | -100.83 Million | -86.58 Million | -12.25 Million |
| Debt repayment | -26.99 Million | -15.37 Million | -414.08 Million | -262.57 Million | -63.94 Million | -14.9 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -159 Thousand | -7.21 Million | - | 2.03 Million | - | -11 Thousand |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -8.44 Million | -7.77 Million | 201.5 Million | 161.73 Million | -22.64 Million | 2.66 Million |
| Accounts receivables | -100.67 Million | -55.73 Million | 126.28 Million | 77.23 Million | -17.92 Million | -128.99 Million |
| Accounts payables | 59.85 Million | 62.17 Million | -94.44 Million | -19.76 Million | 33.07 Million | 42.72 Million |
| Inventory | -23.24 Million | -12.2 Million | -126.18 Million | -23.09 Million | -42.56 Million | -38.01 Million |
| Other working capital | 7.34 Million | -6.21 Million | 94.33 Million | 19.31 Million | -7.32 Million | 3.86 Million |
| Cash at beginning of period | 51.61 Million | 99.1 Million | 35.22 Million | 95.6 Million | 114.58 Million | 151.06 Million |
| Cash at end of period | 49.62 Million | 51.61 Million | 99.1 Million | 99.1 Million | 95.6 Million | 114.58 Million |
| Capital Expenditure | -11.45 Million | -19.76 Million | -69.18 Million | -31.69 Million | -13.47 Million | -12.28 Million |
| Effect of forex changes on cash | -101 Thousand | -165 Thousand | 65 Thousand | 201 Thousand | -301 Thousand | -602 Thousand |
| Net cash flow / Change in cash | -1.99 Million | -47.49 Million | 63.88 Million | 3.5 Million | -18.97 Million | -36.48 Million |
| Free Cash Flow | 28.2 Million | -24.17 Million | 276.38 Million | 104.13 Million | 67.91 Million | -23.62 Million |
5572
300198
DOCN
ILPMY
9878
1260